Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
Terns Pharmaceuticals (Nasdaq: TERN) has announced key leadership changes. Elona Kogan, Esq., has been appointed as the new Chief Legal Officer, bringing over 20 years of experience in the life sciences sector. Meanwhile, Mark Vignola, Ph.D., the current Chief Financial Officer, will be transitioning out by January 2025 or upon the appointment of a successor. Bryan Yoon, Esq., Chief Operating Officer, will remain until September 3, 2024, to assist with the transition.
These changes come as Terns, a clinical-stage biopharmaceutical company, continues to advance its pipeline of small-molecule product candidates for serious diseases, including oncology and obesity. CEO Amy Burroughs expressed confidence in the company's future, highlighting the experienced leadership team and upcoming data readouts from their pipeline.
Terns Pharmaceuticals (Nasdaq: TERN) ha annunciato importanti cambiamenti nella leadership. Elona Kogan, Esq. è stata nominata nuovo Chief Legal Officer, portando con sé oltre 20 anni di esperienza nel settore delle scienze della vita. Nel frattempo, Mark Vignola, Ph.D., l'attuale Chief Financial Officer, passerà il testimone entro gennaio 2025 o all'atto della nomina di un successore. Bryan Yoon, Esq., Chief Operating Officer, rimarrà fino al 3 settembre 2024 per assistere nella transizione.
Questi cambiamenti avvengono mentre Terns, una compagnia biofarmaceutica in fase clinica, continua a far progredire il suo portafoglio di candidati a piccoli molecole per malattie gravi, inclusi oncologia e obesità. L'amministratore delegato Amy Burroughs ha espresso fiducia nel futuro dell'azienda, evidenziando il team di leadership esperto e i prossimi risultati dai loro progetti.
Terns Pharmaceuticals (Nasdaq: TERN) ha anunciado cambios clave en el liderazgo. Elona Kogan, Esq. ha sido nombrada como la nueva Chief Legal Officer, trayendo más de 20 años de experiencia en el sector de las ciencias de la vida. Mientras tanto, Mark Vignola, Ph.D., el actual Chief Financial Officer, estará en proceso de transición para enero de 2025, o bien al nombrar a un sucesor. Bryan Yoon, Esq., Chief Operating Officer, permanecerá hasta el 3 de septiembre de 2024 para ayudar con la transición.
Estos cambios ocurren mientras Terns, una compañía biofarmacéutica en etapa clínica, continúa avanzando en su línea de candidatos a productos de pequeñas moléculas para enfermedades graves, incluyendo oncología y obesidad. La CEO Amy Burroughs expresó confianza en el futuro de la empresa, destacando al experimentado equipo de liderazgo y los próximos resultados de sus ensayos.
Terns Pharmaceuticals (Nasdaq: TERN)는 주요 리더십 변화를 발표했습니다. Elona Kogan, Esq.가 새로운 Chief Legal Officer로 임명되어 생명 과학 분야에서 20년 이상의 경험을 가져왔습니다. 한편, 현재 Chief Financial Officer인 Mark Vignola, Ph.D.는 2025년 1월 또는 후임자가 임명될 때까지 직무에서 물러날 예정입니다. Bryan Yoon, Esq., Chief Operating Officer는 전환을 돕기 위해 2024년 9월 3일까지 재직할 것입니다.
이러한 변화는 Terns가 임상 단계의 생물 의약 회사로서 심각한 질병, 특히 암과 비만을 위한 소분자 제품 후보를 계속 발전시키는 가운데 발생했습니다. CEO Amy Burroughs는 숙련된 리더십 팀과 그들의 파이프라인에서 나올 예정인 데이터에 대한 자신감을 표현했습니다.
Terns Pharmaceuticals (Nasdaq: TERN) a annoncé des changements clés dans sa direction. Elona Kogan, Esq. a été nommée nouvelle Chief Legal Officer, apportant plus de 20 ans d'expérience dans le secteur des sciences de la vie. Entre-temps, Mark Vignola, Ph.D., l'actuel Chief Financial Officer, sera en transition d'ici janvier 2025 ou dès la nomination d'un successeur. Bryan Yoon, Esq., Chief Operating Officer, restera jusqu'au 3 septembre 2024 pour aider à la transition.
Ces changements interviennent alors que Terns, une société biopharmaceutique en phase clinique, continue de faire progresser son portefeuille de candidats produits à petites molécules pour des maladies graves, y compris l'oncologie et l'obésité. La PDG Amy Burroughs a exprimé sa confiance dans l'avenir de l'entreprise, soulignant l'équipe de direction expérimentée et les prochaines annonces de données de leur pipeline.
Terns Pharmaceuticals (Nasdaq: TERN) hat wichtige Führungswechsel angekündigt. Elona Kogan, Esq. wurde zur neuen Chief Legal Officer ernannt und bringt über 20 Jahre Erfahrung im Bereich der Lebenswissenschaften mit. In der Zwischenzeit wird Mark Vignola, Ph.D., der derzeitige Chief Financial Officer, bis Januar 2025 oder bis zur Ernennung eines Nachfolgers ausscheiden. Bryan Yoon, Esq., Chief Operating Officer, wird bis zum 3. September 2024 bleiben, um bei der Übergabe zu helfen.
Diese Veränderungen erfolgen, während Terns, ein biopharmazeutisches Unternehmen in der klinischen Phase, weiterhin seine Pipeline kleiner Moleküle für ernsthafte Krankheiten, einschließlich Onkologie und Fettleibigkeit, vorantreibt. CEO Amy Burroughs äußerte Vertrauen in die Zukunft des Unternehmens und hob das erfahrene Führungsteam sowie bevorstehende Datenberichte aus ihrer Pipeline hervor.
- Appointment of experienced biotech executive Elona Kogan as Chief Legal Officer
- Planned and orderly transition of CFO position, with current CFO staying until January 2025 or until a successor is found
- Company pipeline advancing towards multiple important data readouts in the coming months
- Departure of current Chief Financial Officer Mark Vignola
- Transition of Chief Operating Officer Bryan Yoon, leaving in September 2024
FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Elona Kogan, Esq., as chief legal officer, effective immediately. Ms. Kogan brings a wealth of industry experience and has successfully guided several biotechnology companies through transformational growth and transactions.
“Elona’s proven leadership and deep industry knowledge make her an ideal addition to the Terns team,” said Amy Burroughs, chief executive officer of Terns. “As we advance our pipeline and execute on our strategic priorities, her expertise will be instrumental in driving our growth and success.”
“I am thrilled to join Terns at this exciting time,” said Ms. Kogan. “The company’s commitment to developing life-changing therapies aligns perfectly with my passion for the industry and working with a highly motivated and accomplished team.”
Ms. Kogan joins Terns with a distinguished career spanning over 20 years in the life sciences sector. Previously, she served as chief legal officer at Seer, Inc., where she played a pivotal role in the company’s IPO and commercialization. She has also held leadership positions at ARIAD Pharmaceuticals, Avanir Pharmaceuticals, and King Pharmaceuticals. Ms. Kogan’s full biography can be viewed on the Terns website.
Bryan Yoon, Esq., chief operating officer, will remain with the company through September 3, 2024 as part of the transition.
In addition, the Company announces that Mark Vignola, Ph.D., chief financial officer, will leave in a planned transition following the appointment of a new chief financial officer. A search is underway, and Dr. Vignola will continue to serve as CFO through the end of January 2025, or until a successor is found.
“On behalf of the Terns’ team and Board, I thank Bryan and Mark for their many contributions to the Company’s growth and development as they have both been integral to Terns’ success to date,” said Ms. Burroughs. “I want to express my personal appreciation to Mark and Bryan for their support throughout my transition as the new CEO during this period of tremendous opportunity at the company. They leave Terns in strong hands with an experienced leadership team committed to advancing the important work they began.”
“I am extremely proud of what we have accomplished at Terns. In recent months, it has been important to me to fully support the onboarding of our new leadership during this exciting time in the company’s development,” stated Dr. Vignola. “I believe now is the right time for me to help transition my successor and subsequently depart from Terns, confident the Company is in a strong position to continue to advance our pipeline with a committed, experienced team and CEO in place. I look forward to continuing to support this team and the company as we advance towards multiple important data readouts from our pipeline in the coming months.”
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator program. For more information, please visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about the Company within the meaning of the federal securities laws, including those related to expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company’s small-molecule product candidates; the potential for the mechanisms of action of the Company’s product candidates to be therapeutic targets for their targeted indications; the Company’s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company’s plans and expectations around the addition of key personnel; and the Company’s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
Who is the new Chief Legal Officer of Terns Pharmaceuticals (TERN)?
When is Mark Vignola, CFO of Terns Pharmaceuticals (TERN), leaving the company?
What is Terns Pharmaceuticals (TERN) focused on developing?
When will Bryan Yoon, COO of Terns Pharmaceuticals (TERN), leave the company?
